Opioid crisis: the Teva laboratory announces an agreement in principle worth more than 4 billion dollars

Opiate crisis: the Teva laboratory announces an agreement in principle at more than 4 billions of dollars


Israeli generic drug maker Teva announced on Tuesday that it has reached an agreement in principle to pay more than $4 billion to the United States to settle lawsuits over its role in the opiate crisis.< /strong> 

The cause of more than 500,000 overdose deaths in 20 years in the United States, this health disaster has given rise to a myriad of proceedings launched by communities. Several companies have already agreed to pay to put an end to it.

“Teva has reached an agreement in principle” with representatives of states, Native American tribes and other plaintiffs “on the financial terms of a nationwide opiate agreement,” the group announced Tuesday at the AFP. occasion of the publication of its second quarter results.

“Teva will pay up to $4.25 billion […] as well as approximately $100 million for the tribes, spread over 13 years,” the Israel-based company added in a statement.

This figure includes the financing, up to 1.2 billion dollars, of distributions of a drug against overdoses.

The agreement does not provide for any recognition of fault on the part of the pharmaceutical group.

Teva, which is the subject of several lawsuits, has already reached agreements with certain American states.

Teva was one of the main manufacturers of generic opiate drugs.

Several companies have announced they are paying hundreds of millions of dollars to end lawsuits over their role in the opioid crisis.

Johnson & Johnson, Purdue and other pharmaceutical companies and distributors are accused of encouraging doctors to overprescribe these drugs even though they knew they were seriously addictive.

90,000 people have died from drug overdoses in 2020, three-quarters of which involved opiates. The US Department of Health estimates that this crisis was responsible for four years of declining life expectancy in 2014, 2015, 2016 and 2017.